Metformin reveals a mitochondrial copper addiction of mesenchymal cancer cells - Sorbonne Université
Journal Articles PLoS ONE Year : 2018

Metformin reveals a mitochondrial copper addiction of mesenchymal cancer cells

Abstract

The clinically approved drug metformin has been shown to selectively kill persister cancer cells through mechanisms that are not fully understood. To provide further mechanistic insights, we developed a drug surrogate that phenocopies metformin and can be labeled in situ by means of click chemistry. Firstly, we found this molecule to be more potent than met-formin in several cancer cell models. Secondly, this technology enabled us to provide visual evidence of mitochondrial targeting with this class of drugs. A combination of fluorescence microscopy and cyclic voltammetry indicated that metformin targets mitochondrial copper, inducing the production of reactive oxygen species in this organelle, mitochondrial dysfunc-tion and apoptosis. Importantly, this study revealed that mitochondrial copper is required for the maintenance of a mesenchymal state of human cancer cells, and that metformin can block the epithelial-to-mesenchymal transition, a biological process that normally accounts for the genesis of persister cancer cells, through direct copper targeting.
Fichier principal
Vignette du fichier
journal.pone.0206764.pdf (1.63 Mo) Télécharger le fichier
pone.0208213.pdf (589.79 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-01935757 , version 1 (27-11-2018)

Licence

Identifiers

Cite

Sebastian Müller, Antoine Versini, Fabien Sindikubwabo, Guillaume Belthier, Supaporn Niyomchon, et al.. Metformin reveals a mitochondrial copper addiction of mesenchymal cancer cells. PLoS ONE, 2018, 13 (11), pp.e0206764. ⟨10.1371/journal.pone.0206764⟩. ⟨hal-01935757⟩
160 View
137 Download

Altmetric

Share

More